Alpha Teknova, Inc.

Alpha Teknova, Inc. (TKNO) Market Cap

Alpha Teknova, Inc. has a market capitalization of .

No quote data available.

CEO: Stephen Gunstream

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

IPO Date: 2021-06-25

Website: https://www.teknova.com

Alpha Teknova, Inc. (TKNO) - Company Information

Market Cap: -|Sector: Healthcare

Company Profile

Alpha Teknova, Inc. supplies vital scientific reagents to the life sciences sector across both the United States and international markets. These crucial materials play a key role in facilitating the exploration, evolution, and ultimate production of biopharmaceutical goods, such as advanced drug treatments, new vaccines, and molecular diagnostic solutions. The company's product offerings encompass pre-filled media plates designed for cell growth and replication; liquid cell culture media and complementary supplements that promote cellular proliferation; and various molecular biology reagents used for the handling, rehydration, and purification of samples. Teknova caters to a diverse clientele within the life sciences arena, including pharmaceutical companies, biotechnology firms, contract development and manufacturing organizations (CDMOs), in vitro diagnostic businesses, and academic and governmental research facilities. Founded in 1996, Alpha Teknova's main office is situated in Hollister, California.

Analyst Sentiment

72%
Strong Buy

From 6 Active Polls

Consensus Target Matrix

Data feed parsing pending...

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$5.25
▲ +5.00% Upside
Low Target
$3.75
-25% Risk
Median Target
$5.10
2% Mid
High Target
$6.25
25% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

```html

📘 ALPHA TEKNOVA INC (TKNO) — Investment Overview

🧩 Business Model Overview

To produce a high-conviction, evergreen equity thesis for TKNO without risking factual errors, the exact operating segment(s) and go-to-market mechanics need confirmation. Please provide (or paste) one of the following: (i) the company’s product/service description from its latest filings, (ii) revenue segment breakdown, or (iii) a brief “what TKNO sells and to whom” summary.

Once defined, the core “how it works” should be mapped as:

  • Value creation step: how TKNO converts inputs (technology, labor, component supply, capital, or feedstock) into an output customers pay for.
  • Delivery mechanism: direct sales vs. channel, project-based vs. subscription, manufacturing/production vs. platform/managed service.
  • Customer stickiness drivers: recurring usage, contract structure, integration depth, regulatory acceptance, or supply-chain dependence.

Until TKNO’s category is confirmed (software/SaaS vs. energy/materials vs. financial services vs. healthcare vs. retail/CPG), moat and competitor comparisons below are presented as an “analysis checklist” rather than a claimed fact pattern.

💰 Revenue Streams & Monetisation Model

For institutional underwriting, TKNO’s revenue model should be categorized into:

  • Recurring revenue: subscriptions, maintenance/support, SaaS seats, usage-based fees, or contracted service renewals.
  • Transactional revenue: license sales, one-time project deliveries, professional services, or product shipments.
  • Intermediation/consumption monetisation: take-rate models, managed volume fees, or consumption-linked royalties.

Margin structure should then be tied to:

  • Cost-of-revenue dynamics: labor intensity vs. scalable platform economics; input costs; logistics; and support/servicing expense.
  • Renewal economics or utilization economics: whether gross margins expand with scale (common in software/platform models) or hinge on throughput/commodity input and logistics (common in energy/materials/logistics).
  • Contractual visibility: whether long-duration contracts reduce demand volatility and improve cash conversion.

🧠 Competitive Advantages & Market Positioning

The moat must be anchored to an actual structural mechanism. Below are the highest-probability moat types by industry archetype; confirm which one matches TKNO.

  • Switching Costs (integration + migration): if TKNO’s offerings require customer-specific integration, migration, or workflow embedding.
  • Network Effects (usage-driven value): if customer adoption increases product utility for other customers.
  • Cost Advantages (scale + procurement + logistics): if TKNO benefits from lower unit costs, efficient supply chain, or geographic/logistical advantages.
  • Intangible Assets (data, know-how, regulatory approvals, IP): if TKNO accumulates proprietary datasets, certification/regulatory acceptance, or protected IP.

COMPETITIVE BENCHMARKING (needs TKNO’s sector confirmation):

  • If TKNO is a software/SaaS business, relevant peer sets often include Salesforce, ServiceNow, and Workday. TKNO’s positioning would be contrasted on integration depth, renewal rates, and ecosystem breadth versus these platforms.
  • If TKNO is an energy/materials or logistics-adjacent business, relevant peer sets often include Nutrien, Mosaic, and Yara (where applicable to fertilizer chains) or their industry equivalents for comparable feedstocks and logistics. TKNO’s differentiation would be assessed on low-cost supply access and terminal/pipeline/logistics footprint.
  • If TKNO is a healthcare/regulated business, relevant peer sets often include IQVIA, Elevance Health, or device/biopharma equivalents depending on the product class. TKNO’s differentiation would be tested via regulatory pathway robustness, clinical evidence depth, and reimbursement/coverage durability.

Provide TKNO’s industry classification (and customer type) to lock these comparisons to the correct competitor set and to avoid mismatched benchmarking.

🚀 Multi-Year Growth Drivers

A defensible 5–10 year thesis should connect to at least one secular tailwind and one execution lever:

  • Secular demand shift: digitization and automation (software/platform), supply-chain localization (materials/logistics), aging demographics (healthcare), or regulatory-driven compliance spend (regulated industries).
  • TAM expansion: whether the addressable market grows via new customer segments, broader use cases, or geographic scaling.
  • Share capture: driven by superior unit economics, better performance, faster deployments/implementation cycles, or lower total cost of ownership.
  • Land-and-expand (for recurring models): expansion through additional modules, higher tiers, larger accounts, or increased consumption.
  • Capacity and throughput scaling (for capital/operations models): growth tied to efficient utilization, contracting strategy, and cost discipline.

⚠ Risk Factors to Monitor

  • Moat erosion risk: feature parity from competitors, commoditization of core functionality, or customer willingness to switch vendors.
  • Regulatory or compliance risk: licensing/permitting changes, reimbursement/coverage shifts, or compliance cost increases (industry-dependent).
  • Capital intensity and balance sheet risk: funding needs for expansion, working capital swings, or cost overruns (industry-dependent).
  • Technology disruption: obsolescence of underlying platforms or faster-than-expected performance requirements (industry-dependent).
  • Concentration risk: dependence on a limited set of large customers, suppliers, or geographies.

📊 Valuation & Market View

Markets typically value TKNO’s category using a small set of repeatable frameworks:

  • Software/SaaS-like businesses: value often tracks long-run recurring revenue quality, gross margin durability, and net retention/expansion characteristics—so EV/EBITDA and P/S are commonly used as anchors.
  • Energy/materials/logistics-like businesses: value often tracks normalized margins, asset utilization, and the robustness of low-cost supply and logistics access—so EV/EBITDA is commonly supplemented by cash flow yield and operating leverage.
  • Regulated/healthcare-like businesses: value often reflects reimbursement/coverage durability, pipeline/clinical differentiation, and regulatory pathway risk—often expressed via discounted cash flow logic around longer-duration cash flows.

Key drivers that typically “move the needle” are (i) visibility into recurring contracted cash flows, (ii) evidence that unit economics improve with scale, and (iii) durability of customer retention or supply access.

🔍 Investment Takeaway

A high-conviction TKNO investment thesis should be built around a clearly demonstrated structural moat—most commonly switching costs (integration + migration), network effects (usage-driven value), cost advantages (scale/procurement/logistics), or intangible assets (data/IP/regulatory acceptance)—and then stress-tested against the specific competitive set in TKNO’s segment.

If you share TKNO’s business description (product/service, customers, segment revenue, and primary competitors), this summary can be converted from an analysis framework into a specific, high-conviction institutional investment note that precisely names the moat and the correct peer group.


⚠ AI-generated — informational only. Validate using filings before investing.

```

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"TKNO reported Q1 2026 revenue of $11.08M and net income of -$4.56M (EPS -$0.08). On a YoY basis, revenue increased from $9.80M in Q1 2025 to $11.08M (+13.1%), while net income improved from -$4.65M to -$4.56M (i.e., losses narrowed by ~1.9%). QoQ, revenue rose from $9.98M in Q4 2025 to $11.08M (+11.0%), and net losses narrowed from -$4.76M to -$4.56M (~-4.2% improvement). Profitability remains weak but shows some stabilization: gross margin improved to 34.2% from 32.5% in Q4 2025 and 30.7% in Q1 2025, while operating margin/ net margin stayed deeply negative (net margin -41.1% in Q1 2026 vs -47.7% in Q4 2025). Operating cash flow was reported as 0 in the quarter, with free cash flow also approximately flat (-$0.22M capex, per statement), while cash declined to $4.31M from $5.91M QoQ, largely reflecting investing cash movements around investment purchases/maturities. Balance sheet leverage is moderate: total assets fell to $98.7M from $103.6M QoQ, equity was stable at $64.9M, and total debt declined to $14.7M with net debt at $10.4M. Shareholder return has been negative: the stock is down -49.2% over 1Y, with no dividend and no buyback evidence provided—so total shareholder value is currently driven by capital losses rather than yield."

Revenue Growth

Neutral

Revenue grew +11.0% QoQ ($9.98M to $11.08M) and +13.1% YoY ($9.80M to $11.08M). Growth is positive but does not yet translate into profitability.

Profitability

Neutral

Losses narrowed slightly YoY (net income -$4.65M to -$4.56M, ~+1.9% improvement) and improved QoQ (~-4.2% loss reduction). Net margin remains very negative at -41.1% vs -47.7% in Q4 2025, with gross margin improving to 34.2%.

Cash Flow Quality

Neutral

Operating cash flow is reported as 0 in Q1 2026, and free cash flow is only slightly negative (-$0.22M). Cash declined QoQ ($5.91M to $4.31M), indicating cash use is not fully resolved.

Leverage & Balance Sheet

Fair

Equity is stable at ~$64.9M (slightly down vs $68.8M QoQ). Total assets decreased QoQ to $98.7M. Total debt fell to $14.7M and net debt to $10.4M, suggesting manageable (not growing) leverage.

Shareholder Returns

Neutral

Stock momentum is weak: 1Y change -49.22%, and there is no dividend (0% yield shown). No buybacks are evidenced in the cash flow.

Analyst Sentiment & Valuation

Neutral

No price target is provided. Valuation multiples are not meaningful given negative earnings (P/E is negative in the dataset). Market performance has been materially negative over 1Y and 6M.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

TKNO delivered a relatively clean Q1 with 13% YoY revenue growth and a meaningful gross margin expansion to 34.2% (+3.5 bps). Clinical Solutions drove the standout performance (up 85% to $2.1M), and management emphasized the strength is broad-based rather than a single large order, with expectations for sustained cadence around ~$2M per quarter or better. The company reiterated 2026 revenue guidance of $42M–$44M (midpoint ~6% growth) and maintained conservative positioning until order durability is clearer, despite signs of improving end-market execution (orders >$25k increasing). On profitability, adjusted EBITDA improved to -$2.0M and gross margin should remain in the mid-30s for 2026, while free cash outflow is guided to < $10M for the full year. Operationally, throughput and digitization initiatives (automated aseptic filling, 3x larger batches, 90 digital batch record migrations) support a path toward 2027 as management targets ~20% revenue growth and adjusted EBITDA positivity in 2027.

AI IconGrowth Catalysts

  • Clinical Solutions revenue up 85% YoY to $2.1M, described as broad-based with diversified customer mix (not a single lumpy order).
  • Incremental annual commercial spend increase of ~$2M (split marketing/sales) expected to show revenue impact by early 2027.
  • Operational throughput gains: tripled high-volume bottle single-batch size and implemented an automated aseptic filling line to reduce labor hours/unit.
  • Digitization progress: migrated 90 of 3,000+ paper batch records to digital in Q1 to improve analytics, visibility, documentation quality, and standardization.

Business Development

  • Large pharma growth referenced in Q1 (no named counterparties).
  • End-market commentary includes growth in life science tools, diagnostics, and biopharma; orders above $25k increasing (customers not named).
  • AI-related wet lab spending: customers rolling out AI capabilities driving increased reagent/data generation demand (no named customers).

AI IconFinancial Highlights

  • Revenue increased 13% YoY; first Q1 in nearly three years with >$11M revenue.
  • Gross margin expanded to 34.2% from 30.7% (+3.5 bps) YoY; gross profit rose to $3.8M from $3.0M.
  • Net loss was $4.6M (-$0.08 diluted) vs $4.6M (-$0.09 diluted) in Q1 2025.
  • Adjusted EBITDA was -$2.0M vs -$2.5M in Q1 2025.
  • Free cash outflow improved to $3.6M from $4.3M (decrease driven by lower cash used in operating activities).
  • Marginal cash rate guidance: each incremental $1 of revenue drops through at ~70% marginal cash rate (with GAAP quarter-to-quarter variability).
  • Gross margin full-year expectation reiterated: mid-30s percentage range.

AI IconCapital Funding

  • Cash, cash equivalents, and short-term investments: $17.8M as of 03/31/2026.
  • Total borrowings: $13.2M as of 03/31/2026.
  • Capital expenditures: $200K in Q1 2026 (same as Q1 2025).
  • Buyback/debt reduction amounts: not disclosed in transcript.

AI IconStrategy & Ops

  • Commercial investment ramp began early 2026; sales/marketing spend on track with ~$2M annual increase to add lead generation, lead qualification infrastructure, and onboard experienced sales associates.
  • Digitization: 90 batch records migrated to digital (of 3,000+ paper batch records).
  • Manufacturing: increased single-batch size by 3x and installed automated aseptic filling line to scale production and reduce labor hours/unit.
  • Growth strategy: drive Lab Essentials customer wallet share and increase active Clinical Solutions customer count.

AI IconMarket Outlook

  • Reiterated 2026 total revenue guidance: $42M to $44M (midpoint implies ~6% growth vs 2025).
  • Expectation: gross margin in the mid-30s percentage range for full-year 2026.
  • Adjusted EBITDA target context: investments imply adjusted EBITDA positive in 2027; annualized adjusted EBITDA positive range at higher spend level: $52M to $57M.
  • Free cash outflow guidance: < $10M for full-year 2026 despite increased commercial investment.
  • Revenue impact from commercial investment: by early 2027.
  • 2027 revenue growth aspiration: approximately 20% revenue growth in 2027.

AI IconRisks & Headwinds

  • Customer order durability remains uncertain; management is waiting for durability before changing 2026 guidance range despite improving early orders.
  • Macro uncertainty persists; stabilization described but “not ready to increase” guidance.
  • Catalog portion ~60% of business: business-day impacts typically matter most for Q4 (explicitly stated that Q1 was not impacted).
  • Clinical Solutions lumpiness acknowledged; quarter-to-quarter revenue lumpiness can occur due to larger average order size, especially with new customers ordering less.

Q&A: Analyst Interest

  • Topic: Clinical funnel mix and pipeline stage distribution: Management said it is similar to 2025 slide disclosure, supporting ~70 therapies. They specified 5 in phase 2/3 nearing completion, 12 in phase 1, and the remainder preclinical, with expectation of increases during 2026 as onboarding continues.
  • Topic: Guide conservatism vs quarter timing/order durability: Management cited macro uncertainty and explicitly stated Q1 was not meaningfully impacted by business-day reversals (more relevant to Q4). CFO characterized the maintained range as prudence given durability questions despite an encouraging start to the year.
  • Topic: Cadence and sustainability of Clinical Solutions momentum: Management characterized Q1 Clinical Solutions as broad-based rather than one-time lumpiness, listing “diversity” and customer mix continuing through the quarter. They guided cadence for the rest of 2026 as roughly ~$2M per quarter or better depending on later-year conditions.

Sentiment: MIXED

Note: This summary was synthesized by AI from the TKNO Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
© 2026 Stock Market Info — Alpha Teknova, Inc. (TKNO) Financial Profile